The company anticipates concluding the trial by the end of this year; topline results will be reported in the first half of next year. Arrowhead Pharmaceuticals has concluded the subject enrolment as planned in the Phase IIb clinical trial of ARO-ANG3 to treat mixed dyslipidemia patients.
A total of 182 subjects were currently enrolled into the trial. The company anticipates concluding the trial by the end of this year while topline results will be reported in the first half of next year.
ARO-ANG3 is an investigational RNA interference (RNAi) therapeutic.
Named ARCHES-2 or AROANG3-2001, the placebo-controlled, double-blind trial will analyse the safety and efficacy of ARO-ANG3 to treat mixed dyslipidemia in adult patients.
The study will also enrol up to nearly 20 additional subjects, who were being screened when the trial reached the planned full enrolment. All dose arms enrolled a minimum of 60 subjects, who were randomised into a 3:1 ratio to receive either a subcutaneous dose of ARO-ANG3 or placebo on day one and week 12.
ARO-ANG3
